Published in N Engl J Med on June 18, 1998
Risk factors for recurrent venous thromboembolism in the European collaborative paediatric database on cerebral venous thrombosis: a multicentre cohort study. Lancet Neurol (2007) 2.63
American College of Medical Genetics consensus statement on factor V Leiden mutation testing. Genet Med (2001) 1.70
Portal vein thrombosis: insight into physiopathology, diagnosis, and treatment. World J Gastroenterol (2010) 1.69
Thrombophilia and pregnancy. Reprod Biol Endocrinol (2003) 1.16
Thrombophilia Due to Factor V and Factor II Mutations and Formation of a Dural Arteriovenous Fistula: Case Report and Review of a Rare Entity. Skull Base (2008) 0.98
Clinical Presentation, Imaging and Treatment of Cerebral Venous Thrombosis (CVT). Interv Neuroradiol (2004) 0.95
Oral contraceptive misuse as a risk factor for cerebral venous and sinus thrombosis. J Res Med Sci (2012) 0.94
Genetic polymorphisms associated with carotid artery intima-media thickness and coronary artery calcification in women of the Kronos Early Estrogen Prevention Study. Physiol Genomics (2012) 0.93
Intracranial dural sinus thrombosis: novel use of a mechanical thrombectomy catheter and review of management strategies. Clin Med Res (2009) 0.93
A potential regulatory role for mRNA secondary structures within the prothrombin 3'UTR. Thromb Res (2010) 0.88
Venous thrombosis--the interaction of genes and environment. N Engl J Med (1998) 0.87
A rare presentation of cerebral venous sinus thrombosis associated with tubercular meningitis. BMJ Case Rep (2013) 0.87
Evaluation of cerebral venous thrombosis secondary to oral contraceptive use in adolescents. Neurol Sci (2014) 0.85
Risk factors and recurrent thrombotic episodes in patients with cerebral venous thrombosis. Blood Transfus (2013) 0.85
Role of pharmacogenomics in drug discovery and development. Indian J Pharmacol (2008) 0.84
Cerebral sinus thrombosis and oral contraceptives. There are limits to predictability. BMJ (1998) 0.82
Cerebral Venous Thrombosis. Curr Treat Options Neurol (2000) 0.82
Prothrombin 20210G/A mutation in two patients with mesenteric ischemia. Dig Dis Sci (1999) 0.82
HELLP Syndrome and Cerebral Venous Sinus Thrombosis Associated with Factor V Leiden Mutation during Pregnancy. Case Rep Obstet Gynecol (2014) 0.81
Thrombophilia: genetic polymorphisms and their association with retinal vascular occlusive disease. Br J Ophthalmol (2001) 0.79
The G79A polymorphism of protein Z gene is an independent risk factor for cerebral venous thrombosis. J Neurol (2008) 0.78
The Jeremiah Metzger Lecture. Hypercoagulable states: challenges and opportunities. Trans Am Clin Climatol Assoc (2001) 0.78
Cerebral venous and sinus thrombosis associated with subcutaneous immunoglobulin injection and oral contraceptive use. Neurol Sci (2011) 0.77
Treatment of acute ischemic stroke: beyond thrombolysis and supportive care. Neurotherapeutics (2011) 0.76
A rare localization of cerebral venous sinus thrombosis. Case report. G Chir (2015) 0.75
Cerebral venous sinus thrombosis presenting in pregnancy and puerperium. BMJ Case Rep (2009) 0.75
Prevalence and Geographical Variation of Prothrombin G20210A Mutation in Patients with Cerebral Vein Thrombosis: A Systematic Review and Meta-Analysis. PLoS One (2016) 0.75
Should Magnetic Resonance Venography be Performed Routinely in all Patients Undergoing Evaluation for Idiopathic Intracranial Hypertension? J Neuroophthalmol (2015) 0.75
Clinical pharmacology and vascular risk. Open Neurol J (2010) 0.75
Hormonal contraceptives and cerebral venous thrombosis risk: a systematic review and meta-analysis. Front Neurol (2015) 0.75
Towards the genetic basis of cerebral venous thrombosis-the BEAST Consortium: a study protocol. BMJ Open (2016) 0.75
[Clinical and therapeutic aspects of post-partum cerebral thrombophlebites]. Pan Afr Med J (2016) 0.75
Factor V Leiden, factor V Cambridge, factor II GA20210, and methylenetetrahydrofolate reductase in cerebral venous and sinus thrombosis: A case-control study. J Res Med Sci (2015) 0.75
Impact of Provoking Risk Factors on the Prognosis of Cerebral Venous Thrombosis in Korean Patients. J Stroke (2016) 0.75
Headache Patterns in Cerebral Venous Sinus Thrombosis. J Neurosci Rural Pract (2017) 0.75
Deep venous thrombosis in a patient with Behçet's disease and homozygous prothrombin (factor II) G20210A mutation on oral contraceptive pills. Rheumatol Int (2005) 0.75
Outbreak of hepatitis A among Italian patients with haemophilia. Lancet (1992) 5.64
Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost (2006) 4.58
Gene deletions correlate with the development of alloantibodies in von Willebrand disease. J Clin Invest (1987) 3.73
Transmission of non-A, non-B hepatitis by heat-treated factor VIII concentrate. Lancet (1985) 3.53
Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol Biomarkers Prev (2001) 3.43
Multivariate statistical and GIS-based approach to identify heavy metal sources in soils. Environ Pollut (2001) 3.22
Effect of the age at which smoking begins on frequency of smoking in adulthood. N Engl J Med (1991) 2.96
Eliminating parvovirus B19 from blood products. Lancet (1994) 2.85
Uncertain times for research on hemophilia and allied disorders. J Thromb Haemost (2005) 2.74
Effects of exposure to air pollution on blood coagulation. J Thromb Haemost (2006) 2.52
Ethnic differences in estrogen metabolism in healthy women. J Natl Cancer Inst (1996) 2.29
Oligospecificity of the cellular adhesion receptor Mac-1 encompasses an inducible recognition specificity for fibrinogen. J Cell Biol (1988) 2.28
Effects on bleeding complications of pharmacogenetic testing for initial dosing of vitamin K antagonists: a systematic review and meta-analysis. J Thromb Haemost (2014) 2.15
Patients with type 3 severe von Willebrand disease are not protected against atherosclerosis: results from a multicenter study in 47 patients. Circulation (2004) 2.12
Heightened interaction between platelets and factor VIII/von Willebrand factor in a new subtype of von Willebrand's disease. N Engl J Med (1980) 2.07
1-Deamino-8-d-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrands' diseases. Lancet (1977) 2.06
Meta- and pooled analysis of GSTT1 and lung cancer: a HuGE-GSEC review. Am J Epidemiol (2006) 2.02
Inherited thrombophilia: pathogenesis, clinical syndromes, and management. Blood (1996) 2.02
Expression studies on a novel type 2B variant of the von Willebrand factor gene (R1308L) characterized by defective collagen binding. J Thromb Haemost (2005) 2.02
Inherited thrombophilia: Part 1. Thromb Haemost (1996) 2.00
The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med (1999) 1.97
Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients. Blood (1996) 1.88
Factor V gene mutation is a risk factor for cerebral venous thrombosis. Thromb Haemost (1996) 1.83
Prothrombotic genetic risk factors in young survivors of myocardial infarction. Blood (1999) 1.81
A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost (2011) 1.75
Re: Endocrine factors and adenocarcinoma of the lung in women. J Natl Cancer Inst (1994) 1.74
Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin): a prospective study of 50 patients. J Thromb Haemost (2007) 1.69
Genetic screening for hemophilia A (classic hemophilia) with a polymorphic DNA probe. N Engl J Med (1985) 1.67
Feasibility of a large prospective study in general practice: an Italian experience. Gruppo di Studio sulla Pressione Arteriosa nell'Anziano. Br Med J (Clin Res Ed) (1987) 1.65
Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review. J Thromb Haemost (2010) 1.62
Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost (2000) 1.62
Effect on blood coagulation of massive intravascular haemolysis. Blood (1969) 1.61
Absence of antibodies to AIDS virus in haemophiliacs treated with heat-treated Factor VIII concentrate. Lancet (1985) 1.60
A 23bp insertion in the endothelial protein C receptor (EPCR) gene impairs EPCR function. Thromb Haemost (2001) 1.57
Different bleeding risk in type 2A and 2M von Willebrand disease: a 2-year prospective study in 107 patients. J Thromb Haemost (2012) 1.57
Purinoceptors on blood platelets: further pharmacological and clinical evidence to suggest the presence of two ADP receptors. Br J Haematol (1995) 1.55
A multicenter pharmacokinetic study of the B-domain deleted recombinant factor VIII concentrate using different assays and standards. J Thromb Haemost (2003) 1.53
Homocysteine, vitamin B12, and serum and erythrocyte folate in peritoneal dialysis and hemodialysis patients. Perit Dial Int (2000) 1.48
Reduction in transmission of hepatitis C after the introduction of a heat-treatment step in the production of C1-inhibitor concentrate. Transfusion (1995) 1.48
Type and location of venous thromboembolism in patients with factor V Leiden or prothrombin G20210A and in those with no thrombophilia. J Thromb Haemost (2006) 1.48
Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. Blood (1998) 1.47
Mechanism of plasminogen activator and factor VIII increase after vasoactive drugs. Br J Haematol (1975) 1.47
Factors affecting adherence to guidelines for antithrombotic therapy in elderly patients with atrial fibrillation admitted to internal medicine wards. Eur J Intern Med (2010) 1.47
Hyperferritinemia, iron overload, and multiple metabolic alterations identify patients at risk for nonalcoholic steatohepatitis. Am J Gastroenterol (2001) 1.47
Rare coagulation disorders. Thromb Haemost (1999) 1.46
Status of present and candidate international reference preparations (IRP) of thromboplastin for the prothrombin time. A report of the Subcommittee for Control of Anticoagulation. Thromb Haemost (1993) 1.45
Risk factors for deep venous thrombosis of the upper extremities. Ann Intern Med (1997) 1.45
Multicentric evaluation of a new PT reagent based on recombinant human tissue factor and synthetic phospholipids. Thromb Haemost (1994) 1.43
Rapid detection of factor V: Q506 mutation using whole blood protein C resistance. Blood Coagul Fibrinolysis (1996) 1.43
A simplified procedure for thromboplastin calibration--the usefulness of lyophilized plasmas assessed in a collaborative study. Thromb Haemost (1996) 1.43
Arg506Gln factor V mutation and cerebral ischemia in the young. Stroke (1996) 1.42
No association between genetic hemochromatosis and alpha1-antitrypsin deficiency. Hepatology (1996) 1.42
Hemophilia and nonprogressing human immunodeficiency virus type 1 infection. Blood (1997) 1.41
Factor VII clotting assay: influence of different thromboplastins and factor VII-deficient plasmas. CISMEL Study Group. Thromb Haemost (1991) 1.40
Focal cerebral ischemia in young adults: a collaborative case-control study. The National Research Council Study Group. Neuroepidemiology (1993) 1.40
Lipid profile during rhGH therapy in pediatric renal transplant patients. Pediatr Transplant (2002) 1.40
Multimeric pattern of plasma and platelet von Willebrand factor is normal in uremic patients. Am J Hematol (1993) 1.40
Functional significance of different human CYP1A1 genotypes. Carcinogenesis (1994) 1.40
Frequency of factor V Arg506 Gln in Italians. Thromb Haemost (1996) 1.39
Publication bias via suppressed criticism. Lancet (1993) 1.39
Resistance to activated protein C mimicking dysfunctional protein C: diagnostic approach. Blood Coagul Fibrinolysis (1996) 1.39
Poor comparability of prothrombin fragment 1 + 2 values measured by two commercial ELISA methods: influence of different anticoagulants and standards. Thromb Haemost (1994) 1.38
Calibration of local systems with lyophilized calibrant plasmas improves the interlaboratory variability of the INR in the Italian external quality assessment scheme. Thromb Haemost (1999) 1.38
Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1-infected patients. J Hum Virol (1999) 1.38
Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia. N Engl J Med (1983) 1.38
Factor VIII:C increases after desmopressin in a subgroup of patients with autosomal recessive severe von Willebrand disease. Br J Haematol (1995) 1.37
Genetic diagnosis of haemophilia and other inherited bleeding disorders. Haemophilia (2006) 1.36
Report of the Working Party on Acquired Inhibitors of Coagulation: studies of the "lupus" anticoagulant. Thromb Haemost (1983) 1.34
Inherited thrombophilia: Part 2. Thromb Haemost (1996) 1.34
Identification of a new congenital defect of platelet function characterized by severe impairment of platelet responses to adenosine diphosphate. Blood (1992) 1.31
Deficiencies of protein C, an inhibitor of blood coagulation. Lancet (1982) 1.28
Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation (1994) 1.28
Effects of secondary prophylaxis started in adolescent and adult haemophiliacs. Haemophilia (2008) 1.28
Platelet volume and shape in relation to aggregation and adhesion. Br J Haematol (1967) 1.27
Mutations in coagulation factors in women with unexplained late fetal loss. N Engl J Med (2000) 1.26
Asymptomatic liver disease in haemophiliacs. J Clin Pathol (1975) 1.26
Congenital factor X deficiency: spectrum of bleeding symptoms in 32 Iranian patients. Br J Haematol (1998) 1.24
The low risk of hepatitis C virus transmission among sexual partners of hepatitis C-infected hemophilic males: an international, multicenter study. Blood (1992) 1.22
Guidelines for the diagnosis and management of von Willebrand disease in Italy. Haemophilia (2002) 1.21
Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non-iron-related chronic liver disease. Hepatology (2001) 1.21
Binding of fibrinogen to human monocytes. J Clin Invest (1986) 1.20
Human parvovirus B19 infection in hemophiliacs first infused with two high-purity, virally attenuated factor VIII concentrates. Am J Hematol (1992) 1.20
Recurrent ischemic attacks in two young adults with lupus anticoagulant. Stroke (1984) 1.20
Severe hemophilia with mild bleeding phenotype: molecular characterization and global coagulation profile. J Thromb Haemost (2009) 1.19
Intestinal side-effects of docetaxel/vinorelbine combination. Lancet (2000) 1.19
Risk of cerebral vein thrombosis and oral contraceptives. Lancet (1998) 1.18
Rare coagulation deficiencies. Haemophilia (2002) 1.18